Drugs & Therapy Perspectives

, Volume 24, Issue 3, pp 1–4 | Cite as

Maraviroc: a guide to its use in HIV-1 infection

Drug and Profile Reports

Keywords

Maraviroc Enfuvirtide Delavirdine Tipranavir CCR5 Antagonist 

References

  1. 1.
    Carter N, Keating GM. Maraviroc. Drugs 2007; 67(15): 2277–88PubMedCrossRefGoogle Scholar
  2. 2.
    Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49(11): 4721–32PubMedCrossRefGoogle Scholar
  3. 3.
    European Medicines Agency. Celsentri: summary of product characteristics [online]. Available from URL: http://emea.europa.eu [Accessed 2007 Dec 7]
  4. 4.
    Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006 May; 80(10): 4909–20PubMedCrossRefGoogle Scholar
  5. 5.
    Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from a phase 2b/3 study in the US and Canada [abstract no. 104bLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)Google Scholar
  6. 6.
    Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract no. 104aLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)Google Scholar
  7. 7.
    Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and MOTIVATE 2 originates from a pre-existing minority of CXCR4-using virus [abstract no. 56 plus poster and oral presentation]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12–16; BarbadosGoogle Scholar
  8. 8.
    Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagnoist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007 Mar; 81(5): 2359–71PubMedCrossRefGoogle Scholar
  9. 9.
    Selzentry™ (maraviroc tablets): US prescribing information. New York: Pfizer Inc., 2007 AugGoogle Scholar
  10. 10.
    Lalezari J, Mayer H. Efficacy and safety of maraviroc in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract no. H-718a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
  11. 11.
    Proestel S. FDA analyses of maraviroc safety data [online]. Available from URL: http://www.fda.gov [Accessed 2007 Jul 23]
  12. 12.
    FDA Maraviroc Review Team. FDA cover memorandum [online]. Available from URL: http://www.fda.gov [Accessed 2007 Apr 25]

Copyright information

© Adis Data Information BV 2008

Personalised recommendations